Johnson & Johnson (JNJ) Financial News - Drugmakers Seek End or Changes to U.S. Medication Naming Rules
Johnson & Johnson (JNJ)
Drugmakers Seek End or Changes to U.S. Medication Naming Rules
& Johnson (JNJ)GlaxoSmithKline Plc (GSK)post on Philly.com.
Pennsylvania. â€œWithout this set of eyes, there is little doubt
that the number of serious errors could be far greater.â€
PhRMA agrees with Cohen that industry and other
stakeholders should meet with the FDA to improve the process,
said Jeffrey Francer, the groupâ€™s assistant general counsel.
Those parties should determine how often name confusion
contributes to medical errors and make the agencyâ€™s review
process more transparent, moving decisions earlier to prevent
approval delays, Francer said today in an interview.
The FDA said in June that J&J and Glaxo should revise
packaging for drugs that have similar names after mix-ups sent
at least five patients to the hospital for taking the wrong
New Brunswick, New Jersey-based J&J, and
Requip, a medicine for Parkinsonâ€™s disease and restless-leg
disorder made by London-based Glaxo.
AstraZeneca Plc (AZN)Dexilant.
firstname.lastname@example.org. ...Open whole article (external link)
Other Financial and Stock Market News concerning Johnson & Johnson
Johnson & Johnson Stock Summary
Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Its Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional and over-the-counter pharmaceutical products under JOHNSON?S, AVEENO, CLEAN & CLEAR, NEUTROGENA, RoC, LUBRIDERM, LISTERINE, REACH, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC names. The company?s Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology, and virology. Its products include REMICADE, a biologic to treat Crohn?s disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and used to treat rheumatoid arthritis; TOPAMAX, for adjunctive and monotherapy use in epilepsy, as well as for treating migraines; PROCRIT that stimulates red blood cell production; RISPERDAL oral, a medication to treat the symptoms of schizophrenia, bipolar mania, and irritability associated with autistic behavior in indicated patients; RISPERDAL CONSTA, an injectable, and INVEGATM Extended-Release tablets to treat schizophrenia; LEVAQUIN and FLOXIN, anti-infective products; CONCERTA, a product for treating attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor; and DURAGESIC/Fentanyl Transdermal, a treatment for chronic pain. Johnson & Johnson?s Medical Devices and Diagnostics segment offers circulatory disease management, orthopaedic joint reconstruction and spinal care and sports medicine, surgical care and women?s health, minimally invasive surgical, blood glucose monitoring and insulin delivery, and diagnostic products, as well as disposable contact lenses. The company was founded in 1886 and is based in New Brunswick, New Jersey.